Eleni Andreopoulou

Eleni Andreopoulou

UNVERIFIED PROFILE

Are you Eleni Andreopoulou?   Register this Author

Register author
Eleni Andreopoulou

Eleni Andreopoulou

Publications by authors named "Eleni Andreopoulou"

Are you Eleni Andreopoulou?   Register this Author

31Publications

506Reads

36Profile Views

PARP Inhibitors in Breast Cancer: Why, How, and When?

Breast Care (Basel) 2018 Jul 20;13(3):216-219. Epub 2018 Jun 20.

Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062717PMC
July 2018

Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.

Clin Breast Cancer 2018 02 1;18(1):e135-e142. Epub 2017 Sep 1.

Department of Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2017.08.013DOI Listing
February 2018

Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients.

Am J Surg Pathol 2017 Sep;41(9):1275-1282

Departments of *Pathology and Laboratory Medicine †Medicine ‡Surgery, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000896DOI Listing
September 2017

Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.

Breast Care (Basel) 2017 Mar 7;12(1):21-28. Epub 2017 Feb 7.

Albert Einstein College of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000455821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465752PMC
March 2017

Breast cancer genomics: challenges in interpretation and application.

Oncologist 2013 ;18(4):e11-2

Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639537PMC
December 2013

Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.

Curr Breast Cancer Rep 2013 Mar;5(1):42-50

Assistant Professor Medicine, Albert Einstein College of Medicine, Department of Oncology, Section of Breast Medical Oncology, Montefiore Medical Center, 1825 Eastchester Road, 2South Rm 60, Bronx, New York 10461, Phone 718-904-2900, Fax 718-904-2890.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12609-012-0097-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579672PMC
March 2013

A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density.

Anticancer Res 2012 Apr;32(4):1327-31

Department of Medicine (Oncology) and NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
April 2012

Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.

Cancer Chemother Pharmacol 2011 Aug 11;68(2):457-63. Epub 2010 Nov 11.

Department of Medical Oncology, Albert Einstein Cancer Center, Bronx, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1510-yDOI Listing
August 2011

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells.

Int J Cancer 2011 Jul 28;129(2):417-23. Epub 2010 Nov 28.

Departments of Hematopathology, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.25690
Publisher Site
http://dx.doi.org/10.1002/ijc.25690DOI Listing
July 2011

Seeing red: anthracyclines for breast cancer.

Oncology (Williston Park) 2011 Feb;25(2):128, 131, 134

Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.

View Article

Download full-text PDF

Source
February 2011

Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.

Anticancer Res 2010 Sep;30(9):3243-7

New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
September 2010

Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.

Cancer 2010 Jul;116(14):3330-7

Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25145DOI Listing
July 2010

Circulating tumor cells as prognostic marker in metastatic breast cancer.

Expert Rev Anticancer Ther 2010 Feb;10(2):171-7

University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, 1155 Herman P Pressler, CPB5.3494 Houston, TX 77230, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.105DOI Listing
February 2010

Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage.

Per Med 2008 May;5(3):211-213

University of Texas, MD Anderson Cancer Center Department of Breast Medical Oncology Unit 1354, 1155 Herman P Pressler, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/17410541.5.3.211DOI Listing
May 2008

Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.

Clin Breast Cancer 2008 Mar;8 Suppl 2:S54-60

Department of Breast Medical Oncology, M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
March 2008